Control group (n = 6) | JIA group (n = 35) | p-value | Biological therapy (n = 25) | No biological therapy (n = 10) | p-value | |
---|---|---|---|---|---|---|
A/H1N1 | ||||||
GMT | ||||||
Pre-vaccine (range) | 31.7 (10 -160) | 47.8 (5-1280) | 0.388 | 45.9 (5 -320) | 52.7 (5 -1280) | 0.504 |
Post-vaccine (range) | 320 (160-1280) | 273.1 (20-2560) | 0.684 | 242.5 (20-2560) | 367.5 (40-2560) | 0.535 |
GMR mean (range) | 6.10 (2.7-22.3) | 5.1 (2.7-85.2) | 0.646 | 4.89 (2.71-85.2) | 5.99 (2.71-30.2) | 0.510 |
Seroprotection | ||||||
Pre-vaccine- n (%) | 3 (50) | 24 (68.6) | 0.375 | 18 (72.0) | 6 (60) | 0.490 |
Post-vaccine- n (%) | 6 (100) | 34 (97.1) | 0.675 | 24 (96) | 10 (100) | 0.521 |
Seroconversion- n(%) | 5 (83.3) | 23 (65.7) | 0.391 | 15 (60) | 8 (80) | 0.260 |
A/H3N2 | ||||||
GMT | ||||||
Pre-vaccine (range) | 22.44 (5-80) | 38.44 (5-2560) | 0.562 | 34.82 (5-80) | 49.2 (5-2560) | 0.334 |
Post-vaccine (range) | 320 (80-2560) | 233.0 (20-2560) | 0.684 | 199.7 (20-2560) | 342.9 (80-2560) | 0.565 |
GMR mean (range) | 8.0 (3.1-35.0) | 4.9 (2.7-22.3) | 0.079 | 4.70 (2.7-13.7) | 5.66 (2.7-22.4) | 0.383 |
Seroprotection | ||||||
Pre-vaccine- n (%) | 3 (50) | 22 (62.9) | 0.551 | 17 (68.0) | 5 (50.0) | 0.319 |
Post-vaccine- n(%) | 6 (100) | 34 (97.1) | 0.675 | 24 (96) | 10 (100) | 0.521 |
Seroconversion- n(%) | 5 (83.3) | 22 (62.9) | 0.328 | 15 (60) | 7 (70) | 0.580 |
Flu B | ||||||
GMT | ||||||
Pre-vaccine (range) | 63.4 (40-80) | 40.8 (5-640) | 0.114 | 26.1 (5-640) | 37.3 (5-320) | 0.912 |
Post-vaccine (range) | 640 (40-2560) | 118.9 (20-1280) | 0.396 | 91.9 (20-1280) | 226.2 (20-1280) | 0.871 |
GMR mean (range) | 4.7 (2.7-8.3) | 3.8 (2.7-9.8) | 0.235 | 3.6 (2.7-9.9) | 4.7 (3.06-6.70) | 0.038 |
Seroprotection | ||||||
Pre-vaccine n (%) | 6 (100) | 24 (68.6) | 0.108 | 17 (68.0) | 7 (70) | 0.908 |
Post-vaccine n (%) | 6 (100) | 31 (88.6) | 0.383 | 22 (88.0) | 9 (90.0) | 0.867 |
Seroconversion n (%) | 4 (66.7) | 17 (48.6) | 0.413 | 9 (36) | 8 (80) | 0.019 |